美国奥密克戎XBB适配型BNT162b2新冠疫苗接种后不良事件风险
本研究基于美国商业保险数据库,纳入2023年9月11日至2024年1月15日接种BNT162b2 XBB新冠疫苗的≥6月龄者113,459人,采用自控风险区间设计比较接种后风险期与对照期20种预设特殊关注不良事件的发生率。结果显示接种后20种预设不良事件风险均未升高,与当前BNT162b2新冠疫苗安全性证据一致。
要点
- 接种BNT162b2 XBB疫苗后20种预设特殊关注不良事件风险均未升高。
- 缺血性卒中相对发生率1.52(95%CI 0.44-5.94),未达统计学显著。
- 心肌炎/心包炎相对发生率1.50(95%CI 0.22-12.61),未达统计学显著。
核心结论
- 在美国≥6月龄商业保险人群中,接种BNT162b2 XBB新冠疫苗后20种预设特殊关注不良事件风险未升高,与当前BNT162b2新冠疫苗安全性证据一致。
研究设计与样本
- 采用自控风险区间设计,比较接种后风险期与对照期20种预设特殊关注不良事件的发生率。
- 纳入美国Optum预裁定数据库中2023年9月11日至2024年1月15日接种BNT162b2 XBB新冠疫苗的≥6月龄商业保险个体113,459人,中位(四分位距)年龄47.1(33.0-59.1)岁。
- 采用精确条件泊松回归估计相对发生率及95%置信区间(CI)。
主要发现
- 当风险期或对照期任一时期发生≥1例事件时计算相对发生率,共涉及10种特殊关注不良事件,接种BNT162b2 XBB新冠疫苗与这些事件的发生率均无显著关联。
- 风险期点估计高于对照期的事件包括:缺血性卒中相对发生率1.52(95%CI 0.44-5.94)、心肌炎/心包炎相对发生率1.50(95%CI 0.22-12.61)、免疫介导性肌炎相对发生率1.44(95%CI 0.83-2.52)、带状疱疹相对发生率1.24(95%CI 0.69-2.28)、非热性惊厥/癫痫发作相对发生率1.22(95%CI 0.86-1.73)。
- 上述估计均未达统计学显著,且多数基于少量事件。
- 在同时接种季节性流感疫苗者的亚组分析中,结果总体相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Limited data exists regarding the safety of the COVID-19 2023-2024 vaccine formulations and whether the safety profiles differ from the original formulations. We evaluated the association between the BNT162b2 XBB COVID-19 vaccine and the risk of 20 pre-specified adverse events of special interest (AESIs). METHODS: We identified commercially-insured individuals in the US age ≥ 6 months who received the BNT162b2 XBB COVID-19 vaccine between September 11, 2023 and January 15, 2024 within the Optum pre-adjudicated database. The self-controlled risk interval design was used to compare the incidence of 20 pre-specified AESIs during a risk period following vaccination to a control period. Relative incidence and 95 % confidence intervals (CI) were estimated using exact conditional Poisson regression. RESULTS: The analysis included 113,459 individuals who received the BNT162b2 XBB COVID-19 vaccine (median [interquartile range] age: 47.1 [33.0-59.1] years). Relative incidence was calculated when ≥1 event occurred in either the risk or control period. For these 10 AESIs, there was no significant association between receipt of the BNT162b2 XBB COVID-19 vaccine and the incidence of any of these AESIs. Point estimates were higher in the risk period compared to the control period for ischemic stroke (relative incidence: 1.52; 95 % CI: 0.44-5.94), myocarditis/pericarditis (relative incidence: 1.50; 95 % CI: 0.22-12.61), immune-mediated myositis (relative incidence: 1.44; 95 % CI: 0.83-2.52), herpes zoster (relative incidence: 1.24; 95 % CI: 0.69-2.28), and non-febrile convulsions/seizures (relative incidence: 1.22; 95 % CI: 0.86-1.73). These estimates were not statistically significant, though most were based on few events. Results were generally similar in subgroup analyses of individuals administered a concomitant seasonal influenza vaccine. CONCLUSIONS: There was no increased risk of 20 pre-specified AESIs following receipt of the BNT162b2 XBB COVID-19 vaccine among US commercially insured individuals aged ≥6 months. Findings are consistent with the current evidence on the safety of BNT162b2 COVID-19 vaccines. Public registration: EUPAS108135.
引用
- Sun JW, Dodge LE, Kim EJ, et al. Risk of adverse events after Omicron XBB-adapted BNT162b2 COVID-19 vaccination in the United States. Vaccine. 2024. PMID: 39700907. doi:10.1016/j.vaccine.2024.126629
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。